Research Article

Effects of Vitamin D₃ Supplementation on Epigenetic Aging in Overweight and Obese African Americans With Suboptimal Vitamin D Status: A Randomized Clinical Trial

Li Chen, PhD,¹ Yanbin Dong, PhD,¹ Jigar Bhagatwala, MBBS, MPH,² Anas Raed, MD,² Ying Huang, BS,¹ and Haidong Zhu, PhD¹

¹Georgia Prevention Institute, Department of Population Sciences and ²Department of Medicine, Medical College of Georgia, Augusta University.

Address correspondence to: Haidong Zhu, MD, PhD, Georgia Prevention Institute, Department of Population Health Sciences, Medical College of Georgia, Augusta University, HS-1640, Augusta, GA 30912. E-mail: hzh@augusta.edu

Received: April 30, 2018; Editorial Decision Date: September 19, 2018

Decision Editor: Anne Newman, MD, MPH

Abstract

Background: We have previously shown that vitamin D supplementation increases telomerase activity, suggesting an anti-aging effect. In this study, we aim to test the hypothesis that vitamin D supplementation would slow down epigenetic aging, a new marker of biological aging. **Methods:** A randomized clinical trial was previously conducted among 70 overweight/obese African Americans with serum 25-hydroxyvitamin D [25(OH)D] < 50 nmol/L, who were randomly assigned into four groups of 600 IU/d, 2,000 IU/d, 4,000 IU/d of vitamin D₃ supplements or placebo followed by 16-week interventions. Whole genome-wide DNA methylation analysis was conducted in 51 participants. DNA methylation ages were calculated according to the Horvath and the Hannum methods. Methylation-based age acceleration index (Δ Age) is defined as the difference between DNA methylation age and chronological age in years. Mixed-effects models were used to evaluate the treatment effects.

Results: Fifty-one participants (aged 26.1 ± 9.3 years, 16% are male) were included in the study. After the adjustment of multi-covariates, vitamin D₃ supplementation of 4,000 IU/d was associated with 1.85 years decrease in Horvath epigenetic aging compared with placebo (p value = .046), and 2,000 IU/d was associated with 1.90 years decrease in Hannum epigenetic aging (p value = .044). Serum 25(OH)D concentrations were significantly associated with decreased Horvath Δ Age only (p values = .002), regardless of treatments.

Conclusions: Our results suggest that vitamin D supplementation may slow down Horvath epigenetic aging. But the effect on Hannum epigenetic aging is not conclusive. Large-scale and longer duration clinical trials are needed to replicate the findings.

Keywords: 25-hydroxyvitamin D, DNA methylation age, Vitamin D insufficiency

In recent years, the concept of epigenetic aging has emerged. In 2013, Horvath's epigenetic clock was developed by Horvath and colleagues which predicts DNA methylation (DNAm) age based on 353 CpG sites (1). In the same year, Hannum and colleagues also formulated a quantitative model of aging based on the methylation levels of 71 CpG sites (2). Since then, epigenetic aging has been associated with several aging diseases such as obesity (3,4), Down syndrome (5), Huntington's disease (6), Werner syndrome (7), and schizophrenia in observational studies (8). Whether epigenetic clock is sensitive to changes in response to a geroprotective intervention remains unknown.

DNAm age measures the cumulative effect of the epigenetic maintenance system. The difference between DNAm age and chronological age has been defined as an index of disproportionate aging. Although it is not yet fully understood what exactly is measured by DNAm age, its relation to individual health and longevity has been observed in several studies. DNAm age acceleration is found to be related to increased incidence of frailty, dementia, cancer, and mortality (9–13).

Some factors are suggested to influence epigenetic aging. Epigenetic age accelerators were found in observational studies, which include obesity (4,14), virus infection (15), stress (16,17), and

exposure to violence (18). Fish intake (14) and exercise (14) may slow down epigenetic aging. Beneficial effects of vitamin D have been widely studied for decades, including improving bone (19) and cardiovascular health (20–22), reducing the risk of diabetes (23,24), autoimmune disease (25–27), cancer (28), and even overall mortality (29). Recent evidence suggests that epigenetic regulation may be one of the underlying mechanisms. We have previously conducted a series of epigenome-wide association studies in youth and young adults, and have shown that vitamin D deficiency is associated with global DNA hypomethylation (30) and locus-specific leukocyte DNA methylation changes (31). In addition, we found that 16 weeks of vitamin D₃ supplementation increased global methylation level in a dose-dependent manner (30). Furthermore, we demonstrated that 16 weeks of vitamin D₃ supplementation increases telomerase activity, suggesting an anti-aging property (32).

Therefore, in this study we tested the hypothesis that vitamin D supplementation would slow down epigenetic aging by taking advantage of a previously completed randomized clinical trial (RCT) among overweight/obese African Americans with suboptimal vitamin D status [25(OH)D < 50 nmol/L].

Materials and Methods

Participants

As previously described (33), 70 overweight/obese African Americans residing in Augusta, Georgia, and surrounding areas were randomized into a double-blinded and placebo-controlled clinical trial (NCT01583621) during December 2011 and November 2012. Inclusion criteria were self-reported African American race, aged between 13–45 years, overweight or obese (body mass index [BMI] ≥ 25 kg/m² for adults and ≥ 85 th percentile for age and sex otherwise), no pregnancy, no known acute or chronic illnesses, no use of any prescription medications, birth control pills, herbal, multi-vitamin or mineral supplementations, and suboptimal vitamin D status [serum 25(OH)D concentrations of ≤ 50 nmol/L]. A total of six participants were lost during the follow-up. The genome-wide DNA methylation was performed in 64 subjects with DNA available samples. Fifty-one participants (aged 26.1 ± 9.3 years, 16% are male) with 99 observations were finally included in this study with completed data of both DNA methylation data and laboratory measurements, among which 48 participants had both baseline and post-test data and were included in the pre-post paired tests, while another three participants only had baseline data or post-test data (Supplementary Figure S1). In accordance with the intention to treat principle, all 99 observations were included in the mixed-effects models (34). Informed consents were obtained from the adults and the guardians of adolescents. The study was approved by the institutional review board (IRB) at the Augusta University.

Randomization and Treatments

The participants were randomly assigned to any one of the four groups 18,000 IU/mo (~600 IU/d), 60,000 IU/mo (~2,000 IU/d), 120,000 IU/mo (~4,000 IU/d) of vitamin D₃ or placebo, and the interventional capsules were provided to the participants by supervised dosing for 16 weeks to maximize compliance. The vitamin D₃ and placebo capsules were provided by the Bio-Tech Pharmacal, Fayetteville, AR, and the AU clinical research pharmacy generated the randomization codes and dispensed the study capsules. The AU clinical pharmacy maintained the randomization codes until

the end of the study and did not have any direct role in the data collection (33).

Measurements and Laboratory Assessments

Height and weight were obtained according to standard procedures and BMI was calculated as weight (kg) divided by height (m²). Fasting blood samples were obtained at baseline and 16 weeks, which were frozen and stored at -80°C until assayed. Serum 25(OH)D concentrations were measured using enzyme immunoassay (Immunodiagnostic Systems, Fountain Hills, AZ). The intra- and inter-assay coefficients of variation were 5.6 and 6.6 %, respectively. Our laboratory is certified by the vitamin D₃ external quality assessment scheme (DEQAS), an international program monitoring accuracy of 25(OH)D measurements. Peripheral blood was collected and sent to the clinical pathology core lab at the Medical College of Georgia within 2 hours for the complete blood count with differential, which included the total leukocyte count and percentages of peripheral blood cell types including neutrophils, lymphocytes, monocytes, eosinophils, and basophils. Immune phenotype (CD3+, CD4+, and CD8+) was performed using flow cytometry.

Genome-Wide DNA Methylation and DNAm Age Calculation

DNA was extracted from stored buffy coat samples using the QIAamp DNA Mini Kit (QIAGEN, Valencia, CA). Genome-wide DNA methylation levels were analyzed by the Illumina Infinium MethylationEPIC Beadchip (Illumina Inc., Denver, CO). In the quality control stage, DNA methylation data was processed using the Minfi package (35). Detectable probes were defined as the probes with detection p value < $1\text{E-}16$ in more than 95% samples; detectable samples were those with detection p value < $1\text{E-}16$ in more than 95% CpG sites.

Horvath DNAm age is defined as a prediction of age based on the DNA methylation levels of 353 CpG sites using the statistical pipeline developed by Horvath where background-corrected β values were pre-processed using the calculator's internal normalization method (1). Hannum DNAm age is calculated based on 71 CpG sites using the prediction function developed by Hannum and colleagues (2). Beta values were normalized via the beta-mixture quantile normalization method (36).

Methylation-based age acceleration index (ΔAge) is defined as the difference between DNA methylation age and chronological age in years ($\Delta\text{Age} = \text{DNAm age} - \text{chronological age}$). Therefore, a negative ΔAge suggests that an individual is biologically younger than the chronological age, while a positive ΔAge means accelerated aging. DNA methylation data processing and DNAm age calculation were accomplished using R version 3.4.0 (R Foundation for Statistical Computing Vienna, Austria).

Statistical Analysis

The general characteristics of the subjects are presented as mean $\pm$ standard deviation (SD) for continuous variables and N (%) for categorical variables. Normality of each continuous variable was tested based on a combination test statistics of skewness and kurtosis. Baseline group differences were determined by analysis of variance (ANOVA) for normally distributed variables or by Kruskal-Wallis test, otherwise. Group differences in proportions at baseline were tested by Fisher's exact test. To test for the significance of changes of continuous measurements from baseline to post-test, two-tailed paired t -test was conducted for variables with normal distribution. Wilcoxon matched-pairs signed-ranks test was used instead to test for non-normal distributed variables.

Mixed-effects regression models for repeated measures were used in an intention-to-treat analysis using all available data. Models for epigenetic aging included the fixed effects of intervention groups (placebo, 600 IU/d, 2,000 IU/d, or 4,000 IU/d), measurement time (baseline or post-test) and their interaction. Participant nested within group was considered a random effect. Previous studies have shown that male (37), obesity (3), and immune function (38) may be associated with the aging process. In addition, a strong negative association between CD4 cells and Hannum aging predictor has been observed in previous studies (9). Therefore, the models were also adjusted for gender, BMI, and CD4 percent. As shown in this study as well as other studies (39), since vitamin D may also affect the immune function, so to estimate the total effect of vitamin D₃ supplementation on epigenetic aging, only the baseline level of CD4 percent was included. Month of visit was also included in the model to account for the seasonal effect. Baseline 25(OH)D concentration was also included in the regression model. Khoury and colleagues observed

that a decrease in slope of the predicted epigenetic age by Horvath clock took place at approximately 60 years, indicating that some loci in the model may change differently with age and that age acceleration measures will themselves be age-dependent. Thus age was further included in the regression model (40).

We also tested the relationship between serum 25(OH)D and DNAm age. Mixed-effects models were carried out using natural log-transformed 25(OH)D concentration as the independent variable, and adjusted for sex, BMI, and CD4 percent.

As we assume that the causal effects of the vitamin D₃ supplementations are mediated by increasing the serum concentrations of 25(OH)D, we further tested the effects using the contamination adjusted intention to treat (CA ITT) technique (41). Instrumental variable (IV) regression analysis was carried out, which took serum concentration of 25(OH)D as endogenous variable, and intervention groups as IVs estimated by limited-information maximum likelihood (LIML). All statistical analysis was performed using Stata version 12.0 (College Station, TX).

Table 1. Baseline Characteristics Among Different Groups

Characteristics	Total	Groups				<i>p</i> value
		Placebo (N = 11)	600 IU/d (N = 12)	2,000 IU/d (N = 15)	4,000 IU/d (N = 12)	
Age (y)	26.1 ± 9.3	30.9 ± 10.5	26.9 ± 10.2	24.1 ± 8.7	23.6 ± 7.1	.347
Horvath DNAm age (y)	27.3 ± 9.9	31.2 ± 11.3	28.3 ± 10.8	26.6 ± 9.9	23.4 ± 6.6	.353
Horvath age acceleration index (y)	1.1 ± 3.8	0.2 ± 4.5	1.5 ± 3.8	2.5 ± 3.4	-0.2 ± 3.2	.676
Hannum DNAm age (y)	28.4 ± 8.2	30.3 ± 10.4	27.2 ± 8.5	29.7 ± 7.3	26.2 ± 6.7	.559
Hannum age acceleration index (y)	2.6 ± 5.3	-0.7 ± 4.1	0.3 ± 4.9	5.6 ± 5.4	2.6 ± 4.8	.012
Male (N)	8 (16)	3 (27)	2 (17)	2 (13)	1 (8)	.719
BMI (kg/m ²)	35.2 ± 6.9	36.2 ± 7.7	34.2 ± 6.1	35.6 ± 6.6	34.9 ± 7.9	.784
25(OH)D (nmol/L)	34.4 ± 9.6	34.4 ± 8.1	33.5 ± 6.8	38.8 ± 11.0	30.1 ± 10.0	.129
CD4 percent (%)	46.6 ± 6.3	46.4 ± 4.2	47.4 ± 7.5	45.4 ± 6.2	47.5 ± 7.3	.705
CD4 counts (cell/mm ³)	861 ± 293	960 ± 324	758 ± 244	824 ± 289	920 ± 307	.333

Note: Statistics display as mean ± standard deviation for continuous variables, and N (%) for categorical variables. Baseline group differences of continuous variables were determined by analysis of variance (ANOVA) for normally distributed variables or by Kruskal-Wallis test, otherwise. Fisher's exact test was carried out on categorical variables.

Figure 1. Correlation of Horvath DNA methylation age and chronological age. y-axis is Horvath DNAm age, and x-axis is chronological age. Round symbols represent baseline observations, while the triangle symbols represent post-test observations. Lines linking round symbols to triangle ones represent changes of each participant from baseline to post-test. Overall pairwise correlation coefficient of Horvath DNAm age and chronological age is 0.90 (*p* value < .001). The correlation was higher in the baseline (*r* = .92, *p* value < .001) than post-test (*r* = .88, *p* value < .001).

Figure 2. Correlation of Hannum DNA methylation age and chronological age. y-axis is Hannum DNAm age, and x-axis is chronological age. Round symbols represent baseline observations, while the triangle symbols represent post-test observations. Lines linking round symbols to triangle ones represent changes of each participant from baseline to post-test. Overall pairwise correlation coefficient of Hannum DNAm age and chronological age is 0.82 (*p* value < .001).

Results

General Characteristics and DNA Methylation Age

Demographics of the participants are shown in Table 1. Fifty-one individuals were included (aged 26.1 ± 9.3 years, 16% are male), 48 of whom had both baseline data and post-test data. Overall DNAm ages were significantly correlated with chronological age (Horvath DNAm age $r = .90$, p value $< .001$, Hannum DNAm age $r = .82$, p value $< .001$) as shown in Figures 1 and 2. The correlations were higher in the baseline (Horvath $r = .92$, p value $< .001$, Hannum DNAm age $r = .82$, p value $< .001$) than those at post-test (Horvath $r = .88$, p value $< .001$, Hannum DNAm age $r = .81$, p value $< .001$) in both DNAm ages. There was no difference in age, DNAm ages, Horvath Δ Age, gender, BMI, 25(OH)D, CD4 percent, and CD4 count among the four groups at baseline (p values $> .05$). However, Hannum Δ Age was significantly different among the four groups ranging from -0.7 years in placebo group to 5.6 years in 2,000 IU/d group (p value = .012).

Changes in Epigenetic Aging and Serum 25(OH)D From Pre- to Post-Vitamin D₃ Supplementation

In Table 2, we compared the changes in Δ Age and 25(OH)D concentration before and after treatment. Average serum 25(OH)D concentration was significantly raised by 22.10, 47.01 and 47.20 nmol/L in 600 IU/d, 2,000 IU/d, and 4,000 IU/d groups (p values $< .001$) as we previously reported (30). Horvath Δ Age was decreased by 1.83 years (p value = .002) and 1.62 years (p value = .031) in 2,000 IU/d and 4,000 IU/d groups after the treatment, respectively. Changes in Hannum Δ Age were not significant (p values $> .05$).

Effects of Vitamin D₃ Supplementation on Epigenetic Aging

In Table 3, model 1 reassigned participants into two groups (assignment 1), which were group 1 including placebo and 600 IU/d, and group 2 including 2,000 IU/d and 4,000 IU/d. Assignment 2 in model 2 was the original assignment of this study, which split the participants into four groups. Effect 1 derived from model 1 was the interaction term of wave and assignment 1, the coefficient of which represented the treatment effect of group 2 compared with group 1. Effect 2 derived from model 2 was the interaction of wave and assignment 2, which reflected

dose-response of vitamin D₃ supplementation on epigenetic aging. Model 1 and model 2 were both adjusted for sex, BMI, group assignment, measure time, month of visit, baseline 25(OH)D concentration and CD4 percent. In model 1, treatment was associated with 1.49 years (p value = .023) decrease in Horvath Δ Age, not with Hannum Δ Age. Results from minimally adjusted model that was only adjusted for sex also showed that treatment was associated with decreased Horvath Δ Age (p value = .008) (Supplementary Table S2). In model 2, vitamin D₃ supplementation was also associated with decreased Δ Age in both epigenetic clocks, but only significant with Horvath Δ Age in 4,000 IU/d group (p value = .046), and Hannum Δ Age in 2,000 IU/d group (p value = .044). We further adjusted for chronological age in the models, and the effects of vitamin D₃ supplementation on epigenetic aging remained unchanged. A set of regressions were also performed to investigate the interaction of age by including the interaction terms of chronological age and treatment, which were not significant.

Association Between Serum 25(OH)D Concentration and Epigenetic Aging

In Table 4, regardless of treatment, the increase in serum 25(OH)D concentrations were only significantly associated with decreased Horvath Δ Age (p values = .002), and the association remained significant after the adjustment of gender, BMI, and CD4 percent (p values = .002). There was no association between Hannum clock and changes in serum 25(OH)D concentrations.

Dose-Effect of Vitamin D₃ Supplementation on the Horvath Epigenetic Aging Mediated by the Changes of Serum 25(OH)D Concentration

To test whether serum 25(OH)D mediated the dose-response of vitamin D₃ supplementation on epigenetic aging, we conducted the IV regression analysis using the Horvath clock since that only the Horvath clock was associated with serum 25(OH)D as mentioned above. The dose responsive increases in serum 25(OH)D concentration induced by vitamin D₃ supplementations were significantly associated with the decreased Horvath epigenetic aging in both IV regression models, which used assignment 1 as IV in model 1 (p value = .019), and assignment 2 as IV in model 2 (p value = .038) (Table 5).

Table 2. Changes of Age Acceleration Index and Serum 25(OH)D Concentration Between Pre- and Post-Intervention Among Different Treatment Groups

Characteristics	Placebo (N = 11)	600 IU/d (N = 10)	2,000 IU/d (N = 15)	4,000 IU/d (N = 12)
Horvath age acceleration index (y)				
Pre	0.22 $\pm$ 4.52	0.89 $\pm$ 3.87	2.52 $\pm$ 3.38	-0.17 $\pm$ 3.19
Post	-0.42 $\pm$ 5.63	1.52 $\pm$ 4.14	0.69 $\pm$ 3.40	-1.80 $\pm$ 4.11
Difference	-0.64 $\pm$ 2.46	0.63 $\pm$ 2.68	-1.83 $\pm$ 1.86	-1.62 $\pm$ 2.27
p value	.410	.477	.002	.031
Hannum age acceleration index (y)				
Pre	-0.69 $\pm$ 4.06	0.62 $\pm$ 5.02	5.65 $\pm$ 5.52	2.56 $\pm$ 4.75
Post	-0.28 $\pm$ 4.19	1.19 $\pm$ 4.04	4.45 $\pm$ 5.31	2.30 $\pm$ 5.01
Difference	0.40 $\pm$ 2.65	0.58 $\pm$ 1.97	-1.20 $\pm$ 3.38	-0.26 $\pm$ 5.54
p value	.623	.375	.192	.728
25(OH)D (nmol/L)				
Pre	34.36 $\pm$ 8.14	33.27 $\pm$ 7.28	38.76 $\pm$ 10.98	30.13 $\pm$ 10.02
Post	41.27 $\pm$ 13.67	55.37 $\pm$ 11.48	85.77 $\pm$ 31.54	77.33 $\pm$ 14.79
Difference	6.91 $\pm$ 10.79	22.10 $\pm$ 12.86	47.01 $\pm$ 27.03	47.20 $\pm$ 16.64
p value	.060	<.001	<.001	<.001

Note: Pre-post changes of continuous variables were determined by t -test for normally distributed variables or by Wilcoxon matched-pairs signed-ranks test, otherwise. Fisher's exact test was carried out on categorical variables.

Table 3. Effects of Vitamin D₃ Supplementation on Horvath and Hannum Epigenetic Aging Based on Mixed-Effects Models

	Horvath Epigenetic Aging			Hannum Epigenetic Aging		
	Model 1		p value	Model 2		p value
	β (95% CI)	Reference group		β (95% CI)	Reference group	
Effect 1						
Group 1 (placebo, 600 IU/d)						
Group 2 (2,000, 4,000 IU/d)	-1.49 (-2.78, -0.21)		.023	—	Reference group	—
Effect 2						
Placebo						
600 IU/d	—	Reference group	—	—	Reference group	—
2,000 IU/d	—	0.14 (-1.86, 2.13)	.892	—	-0.81 (-2.94, 1.33)	.940
4,000 IU/d	—	-1.07 (-2.81, 0.67)	.228	—	-1.90 (-3.75, -0.05)	.044
Female	—	-1.85 (-3.66, -0.03)	.046	—	-0.78 (-2.72, 1.16)	.344
BMI	-1.95 (-4.88, 0.98)		.193	0.34 (-3.67, 4.36)		.868
Baseline 25(OH)D	0.14 (-0.00, 0.11)		.050	0.06 (-0.13, 0.25)		.532
CD4 percent	0.003 (-0.10, 0.11)		.950	-0.09 (-0.23, 0.06)		.248
	-0.12 (-0.28, 0.03)		.125	-0.27 (-0.48, -0.06)		.012
						.017

Note: BMI = body mass index. Totally 99 observations of 51 participants. Models were adjusted for sex, BMI, group assignment, measure time, month of visit, baseline 25(OH)D concentration and CD4 percent. Model 1 used assignment 1 that reassigned participants into two groups, which were group 1 including placebo and 600 IU/d, and group 2 including 2,000 IU/d and 4,000 IU/d. Effect 1 was the interaction term of wave and assignment 1. Model 2 used assignment 2, which was the original design of this study. Effect 2 was the interaction of wave and assignment 2.

Table 4. Association Between Changes in Serum 25(OH)D Concentration and Horvath and Hannum Epigenetic Aging Based on Mixed-Effects Models

	Horvath Epigenetic Aging			Hannum Epigenetic Aging		
	Model 1		p value	Model 2		p value
	β (95% CI)	Reference group		β (95% CI)	Reference group	
25(OH)D	-1.35 (-2.21, -0.48)		.002	-1.42 (-2.29, -0.54)		.002
Female	—		.489	-1.12 (-4.28, 2.05)		.598
BMI	—		.220	0.09 (-0.05, 0.24)		—
CD4 percent	—		.089	-0.15 (-0.32, 0.02)		—
						.514
						.693
						.320
						.016

Note: BMI = body mass index. Totally 99 observations of 51 participants. Model 1 was unadjusted, model 2 was adjusted for sex, BMI and CD4%. 25(OH)D concentration was natural log transformed.

Discussion

In this study, we found that the DNAm age estimated by either Horvath clock or Hannum clock was highly correlated with chronological age in African Americans with suboptimal vitamin D status at the baseline. Vitamin D₃ supplementation decreased DNA methylation aging. More specifically, the epigenetic aging was significantly decreased by 4,000 IU/d vitamin D₃ supplementation according to the Horvath clock, and 2,000 IU/d was more effective according to the Hannum clock. Moreover, serum 25 (OH)D levels were only negatively associated with DNA methylation aging measured by the Horvath clock.

Studies in mice suggest that caloric restriction slows epigenetic aging and DNA methylation drift (42,43). However, whether epigenetic clock changes in response to a geroprotective intervention in humans remains unknown. To the best of our knowledge, this is the first study to evaluate the effect of vitamin D₃ supplementation on epigenetic aging in humans using an RCT design.

DNAm age is a prediction of age based on individual DNA methylation levels with high accuracy (1), and has been employed by a number of studies and validated with a high correlation between DNAm age and chronological age (8,44). In the present study, we observed that DNA methylation age calculated by either the Horvath method or the Hannum method was both highly correlated with chronological age in African Americans. The unadjusted correlation analysis showed that this correlation was higher at the baseline than post-test, suggesting that the vitamin D₃ supplementation may have driven the DNAm age to deviate from the chronological age.

The present study explored the treatment effect of vitamin D₃ supplementation on three doses (600 IU/d, 2,000 IU/d, and 4,000 IU/d). Compared with placebo, both 2,000 IU and 4,000 IU group decreased epigenetic aging by either clock. However, the associations between vitamin D₃ supplementations and epigenetic aging were different between the Horvath and Hannum clocks. The epigenetic aging was significantly decreased by 4,000 IU/d vitamin D₃ supplementation according to the Horvath clock, and 2,000 IU/d was more effective according to the Hannum clock. This discrepancy may be due to the fact that only 6 CpG sites overlap between these two epigenetic clocks (9). In addition, they were built to represent different tissues. Horvath is a multi-tissue clock built to capture more variation while Hannum only applies to blood leukocytes (44). It may also due to the small sample size. In addition, the increase in serum 25(OH)D concentration by vitamin D₃ supplementations was associated with the decrease in Horvath epigenetic aging regardless of groups. Future large-scale studies are needed to confirm our findings.

Accelerated epigenetic aging was considered a predictor of mortality (45), and was associated with higher all-cause mortality, cancer mortality and cardiovascular mortality (10). Meta-analyses have shown that vitamin D supplementation was associated with decreased overall mortality (46,47). We have also shown that vitamin D supplementation increases telomerase activity, which may help slow down the cellular aging process in the African American population (32). The present study suggests that vitamin D supplementation may also slow down the epigenetic aging process.

Most of previous studies on epigenetic aging are cross-sectional, which cannot establish causal relationships between risk factors, such as nutrients, physical measurements and environments, and epigenetic aging, and unable to observe the changes of DNAm age overtime (14,16). Some studies have tracked down the longitudinal changes of epigenetic aging and transcriptional response, however, RCTs can establish causal relationships (4,18,48,49). In this study, an RCT was carried out and measurements were taken both before and after the intervention, which allowed us to observe the longitudinal changes of the epigenetic aging, and infer the causal relationship between vitamin D supplementation and epigenetic aging.

We tested the test-retest reliability of these two epigenetic clocks in our study (Supplementary Table S1). The coefficients of variation between the baseline and post-test measurements were 8.36% for the Horvath clock and 8.74% for the Hannum clock suggesting that the measurements of epigenetic clock between the two visits were highly correlated and reproducible. The correlation between the baseline and post-test of the Horvath clock was the highest in the placebo group, possibly due to that fact that vitamin D supplementation may have driven the DNAm age to deviate from the chronological age.

There are several strengths in our study. First, to the best of our knowledge, this is the first study to evaluate the effect of a nutritional intervention on epigenetic aging utilizing a randomized controlled clinical trial design, which could help to establish a causal relationship. Second, our study focused on the African American population with suboptimal vitamin D status and who are prone to higher risk for age-related diseases (50). However, our power for repeated measurements was estimated to be modest with 16% to detect the difference in Δ Age changes between placebo and the 4,000 IU/d group, and 70% to detect the difference in Δ Age changes between two groups (placebo/600 IU/d vs 2,000/4,000 IU/d). Of note, this is an ancillary study, which was not originally designed to test this hypothesis. Therefore, there is a considerable likelihood of both false-positive and false-negative results. Further large-scale studies are needed to validate our results and address dose-response effects of vitamin D supplement on epigenetic aging. We observed a decreased epigenetic

Table 5. Associations Between the Changes of Horvath Epigenetic Aging and the Changes of 25(OH)D Concentration Induced by Vitamin D₃ Supplementation Based on Instrumental Variable Models

	Model 1		Model 2	
	β (95% CI)	<i>p</i> value	β (95% CI)	<i>p</i> value
25(OH)D	-0.04 (-0.08, -0.01)	.019	-0.04 (-0.08, -0.00)	.038
Female	-2.89 (-4.96, -0.81)	.006	-2.89 (-4.93, -0.85)	.005
BMI	-0.02 (-0.14, 0.10)	.764	-0.02 (-0.13, 0.10)	.781
Baseline 25(OH)D	-0.02 (-0.11, 0.07)	.672	-0.02 (-0.10, 0.07)	.661
CD4 percent	0.05 (-0.08, 0.17)	.476	0.05 (-0.07, 0.17)	.440

Note: BMI = body mass index. Model 1 used assignment 1 as instrumental variable that reassigned participants into two groups, which were group 1 including placebo and 600 IU/d, and group 2 including 2,000 IU/d and 4,000 IU/d. Model 2 used assignment 2 as instrumental variable, which was the original design of this study. 25(OH)D concentration was natural log transformed.

aging by 16-week vitamin D supplementation in overweight African American population. Whether this geroprotective effect of vitamin D supplementation can be sustained over longer period is unknown. Also unknown is whether this anti-biological aging effect exists in other populations. Future longer term RCTs in other populations are warranted.

Biological aging measures have been proposed as proxies for extension of healthy lifespan. Belsky and colleagues found that biological aging measured by two other clinical algorithms are sensitive enough to detect effects of geroprotective therapy in a small randomized trial (51). We were also able to detect significant changes in DNA methylation aging induced by vitamin D₃ supplementation in a relatively small RCT, which suggest that markers of biological aging such as epigenetic aging can be used as endpoints in RCTs that aim to extend healthy lifespan.

Conclusion

For the first time, our results suggest that vitamin D₃ supplementation may slow down the Horvath epigenetic aging process in overweight/obese African Americans with suboptimal vitamin D status. But the effect on the Hannum epigenetic aging is not conclusive. Future longer term and large-scale RCTs in other populations are warranted to validate our findings.

Supplementary Material

Supplementary data are available at *The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences* online.

Funding

This work was supported by American Heart Association (Southeast Affiliate) (14GRNT20480211).

Conflict of Interest

None declared.

References

- Horvath S. DNA methylation age of human tissues and cell types. *Genome Biol.* 2013;14:R115. doi:10.1186/gb-2013-14-10-r115
- Hannum G, Guinney J, Zhao L, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. *Mol Cell.* 2013;49:359–367. doi:10.1016/j.molcel.2012.10.016
- Horvath S, Erhart W, Brosch M, et al. Obesity accelerates epigenetic aging of human liver. *Proc Natl Acad Sci USA.* 2014;111:15538–15543. doi:10.1073/pnas.1412759111
- Nevalainen T, Kananen L, Marttila S, et al. Obesity accelerates epigenetic aging in middle-aged but not in elderly individuals. *Clin Epigenetics.* 2017;9:20. doi:10.1186/s13148-016-0301-7
- Horvath S, Garagnani P, Bacalini MG, et al. Accelerated epigenetic aging in down syndrome. *Aging Cell.* 2015;14:491–495. doi:10.1111/acel.12325
- Horvath S, Langfelder P, Kwak S, et al. Huntington's disease accelerates epigenetic aging of human brain and disrupts DNA methylation levels. *Aging (Albany NY).* 2016;8:1485–1512. doi:10.18632/aging.101005
- Maierhofer A, Flunkert J, Oshima J, Martin GM, Haaf T, Horvath S. Accelerated epigenetic aging in Werner syndrome. *Aging (Albany NY).* 2017;9:1143–1152. doi:10.18632/aging.101217
- Voisey J, Lawford BR, Morris CP, et al. Epigenetic analysis confirms no accelerated brain aging in schizophrenia. *npj Schizophr.* 2017;3:26. doi:10.1038/s41537-017-0026-4
- Marioni RE, Shah S, McRae AF, et al. DNA methylation age of blood predicts all-cause mortality in later life. *Genome Biol.* 2015;16:25. doi:10.1186/s13059-015-0584-6
- Perna L, Zhang Y, Mons U, Hollecsek B, Saum KU, Brenner H. Epigenetic age acceleration predicts cancer, cardiovascular, and all-cause mortality in a German case cohort. *Clin Epigenetics.* 2016;8:64. doi:10.1186/s13148-016-0228-z
- Breitling LP, Saum KU, Perna L, Schöttker B, Hollecsek B, Brenner H. Frailty is associated with the epigenetic clock but not with telomere length in a German cohort. *Clin Epigenetics.* 2016;8:21. doi:10.1186/s13148-016-0186-5
- Degerman S, Josefsson M, Nordin Adolfsson A, et al. Maintained memory in aging is associated with young epigenetic age. *Neurobiol Aging.* 2017;55:167–171. doi:10.1016/j.neurobiolaging.2017.02.009
- Zheng Y, Joyce BT, Colicino E, et al. Blood epigenetic age may predict cancer incidence and mortality. *EBioMedicine.* 2016;5:68–73. doi:10.1016/j.ebiom.2016.02.008
- Quach A, Levine ME, Tanaka T, et al. Epigenetic clock analysis of diet, exercise, education, and lifestyle factors. *Aging (Albany NY).* 2017;9:419–446. doi:10.18632/aging.101168
- Levine AJ, Quach A, Moore DJ, et al. Accelerated epigenetic aging in brain is associated with pre-mortem HIV-associated neurocognitive disorders. *J Neurovirol.* 2016;22:366–375. doi:10.1007/s13365-015-0406-3
- Wolf EJ, Logue MW, Hayes JP, et al. Accelerated DNA methylation age: associations with PTSD and neural integrity. *Psychoneuroendocrinology.* 2016;63:155–162. doi:10.1016/j.psyneuen.2015.09.020
- Zannas AS, Arloth J, Carrillo-Roa T, et al. Lifetime stress accelerates epigenetic aging in an urban, African American cohort: relevance of glucocorticoid signaling. *Genome Biol.* 2015;16:266. doi:10.1186/s13059-015-0828-5
- Jovanovic T, Vance LA, Cross D, et al. Exposure to violence accelerates epigenetic aging in children. *Sci Rep.* 2017;7:8962. doi:10.1038/s41598-017-09235-9
- Reid IR, Bolland MJ, Grey A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. *Lancet.* 2014;383:146–155. doi:10.1016/S0140-6736(13)61647-5
- Harris RA, Pedersen-White J, Guo DH, et al. Vitamin D₃ supplementation for 16 weeks improves flow-mediated dilation in overweight African-American adults. *Am J Hypertens.* 2011;24:557–562. doi:10.1038/ajh.2011.12
- Parikh S, Guo DH, Pollock NK, et al. Circulating 25-hydroxyvitamin D concentrations are correlated with cardiometabolic risk among American black and white adolescents living in a year-round sunny climate. *Diabetes Care.* 2012;35:1133–1138. doi:10.2337/dc11-1944
- Williams DM, Fraser A, Sayers A, et al. Associations of 25-hydroxyvitamin D₂ and D₃ with cardiovascular risk factors in childhood: cross-sectional findings from the Avon Longitudinal Study of Parents and Children. *J Clin Endocrinol Metab.* 2012;97:1563–1571. doi:10.1210/jc.2011-2335
- Seida JC, Mitri J, Colmers IN, et al. Clinical review: effect of vitamin D₃ supplementation on improving glucose homeostasis and preventing diabetes: a systematic review and meta-analysis. *J Clin Endocrinol Metab.* 2014;99:3551–3560. doi:10.1210/jc.2014-2136
- Belenchia AM, Tosh AK, Hillman LS, Peterson CA. Correcting vitamin D insufficiency improves insulin sensitivity in obese adolescents: a randomized controlled trial. *Am J Clin Nutr.* 2013;97:774–781. doi:10.3945/ajcn.112.050013
- Aranow C, Kamen DL, Dall'Era M, et al. Randomized, double-blind, placebo-controlled trial of the effect of vitamin D₃ on the interferon signature in patients with systemic lupus erythematosus. *Arthritis Rheumatol.* 2015;67:1848–1857. doi:10.1002/art.39108
- Kamen DL, Oates JC. A pilot study to determine if vitamin D repletion improves endothelial function in lupus patients. *Am J Med Sci.* 2015;350:302–307. doi:10.1097/MAJ.0000000000000556
- Yip KH, Kolesnikoff N, Yu C, et al. Mechanisms of vitamin D₃ metabolite repression of IgE-dependent mast cell activation. *J Allergy Clin Immunol.* 2014;133:1356–1364. doi:10.1016/j.jaci.2013.11.030

28. Autier P, Boniol M, Pizot C, Mullie P. Vitamin D status and ill health: a systematic review. *Lancet Diabetes Endocrinol.* 2014;2:76–89. doi:10.1016/S2213-8587(13)70165-7
29. Afzal S, Brøndum-Jacobsen P, Bojesen SE, Nordestgaard BG. Genetically low vitamin D concentrations and increased mortality: Mendelian randomisation analysis in three large cohorts. *BMJ.* 2014;349:g6330. doi:10.1136/bmj.g6330
30. Zhu HD, Bhagatwala J, Huang Y, et al. Race/ethnicity-specific association of vitamin D and global DNA methylation: cross-sectional and interventional findings. *PLoS One.* 2016;11:e0152849. doi:10.1371/journal.pone.0152849
31. Zhu HD, Wang XL, Shi HD, et al. A genome-wide methylation study of severe vitamin D deficiency in African American adolescents. *J Pediatr-Us.* 2013;162:1004–1009.e1. doi:10.1016/j.jpeds.2012.10.059
32. Zhu H, Guo D, Li K, et al. Increased telomerase activity and vitamin D supplementation in overweight African Americans. *Int J Obes (Lond).* 2012;36:805–809. doi:10.1038/ijo.2011.197
33. Bhagatwala J, Zhu H, Parikh SJ, et al. Dose and time responses of vitamin D biomarkers to monthly vitamin D3 supplementation in overweight/obese African Americans with suboptimal vitamin D status: a placebo controlled randomized clinical trial. *BMC Obes.* 2015;2:27. doi:10.1186/s40608-015-0056-2
34. White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for intention to treat analysis in randomised trials with missing outcome data. *BMJ.* 2011;342:d40. doi:10.1136/bmj.d40
35. Aryee MJ, Jaffe AE, Corrada-Bravo H, et al. Minfi: a flexible and comprehensive bioconductor package for the analysis of Infinium DNA methylation microarrays. *Bioinformatics.* 2014;30:1363–1369. doi:10.1093/bioinformatics/btu049
36. Teschendorff AE, Marabita F, Lechner M, et al. A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. *Bioinformatics.* 2013;29:189–196. doi:10.1093/bioinformatics/bts680
37. Simpkin AJ, Hemani G, Suderman M, et al. Prenatal and early life influences on epigenetic age in children: a study of mother-offspring pairs from two cohort studies. *Hum Mol Genet.* 2016;25:191–201. doi:10.1093/hmg/ddv456
38. Kalokerinos EK, von Hippel W, Henry JD, Trivers R. The aging positivity effect and immune function: positivity in recall predicts higher CD4 counts and lower CD4 activation. *Psychol Aging.* 2014;29:636–641. doi:10.1037/a0037452
39. Aziz M, Livak B, Burke-Miller J, et al. Vitamin D insufficiency may impair CD4 recovery among Women's Interagency HIV Study participants with advanced disease on HAART. *AIDS.* 2013;27:573–578. doi:10.1097/QAD.0b013e32835b9ba1
40. El Khoury LY, Gorrie-Stone T, Smart M, et al. Properties of the epigenetic clock and age acceleration. *bioRxiv.* 2018;363143.
41. Sussman JB, Hayward RA. An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials. *BMJ.* 2010;340:c2073. doi:10.1136/bmj.c2073
42. Wang T, Tsui B, Kreisberg JF, et al. Epigenetic aging signatures in mice livers are slowed by dwarfism, caloric restriction and rapamycin treatment. *Genome Biol.* 2017;18:57. doi:10.1186/s13059-017-1186-2
43. Maegawa S, Lu Y, Tahara T, et al. Caloric restriction delays age-related methylation drift. *Nat Commun.* 2017;8:539. doi:10.1038/s41467-017-00607-3
44. Marioni RE, Suderman M, Chen BH, et al. Tracking the epigenetic clock across the human life course: a meta-analysis of longitudinal cohort data. *J Gerontol A Biol Sci Med Sci.* 2018;74:57–61. doi:10.1093/gerona/gly060
45. Marioni RE, Harris SE, Shah S, et al. The epigenetic clock and telomere length are independently associated with chronological age and mortality. *Int J Epidemiol.* 2016;45:424–432. doi:10.1093/ije/dyw041
46. Zheng Y, Zhu J, Zhou M, Cui L, Yao W, Liu Y. Meta-analysis of long-term vitamin D supplementation on overall mortality. *PLoS One.* 2013;8:e82109. doi:10.1371/journal.pone.0082109
47. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. *Arch Intern Med.* 2007;167:1730–1737. doi:10.1001/archinte.167.16.1730
48. Lei MK, Simons RL, Beach SR, Philibert RA. Neighborhood disadvantage and biological aging: using marginal structural models to assess the link between neighborhood census variables and epigenetic aging. *J Gerontol B Psychol Sci Soc Sci.* 2017. doi:10.1093/geronb/gbx015
49. Belsky DW. Life-course longitudinal studies are needed to advance integration of genomics and social epidemiology. *Am J Epidemiol.* 2018;187:1337–1338. doi:10.1093/aje/kwy060
50. Dong Y, Pollock N, Stallmann-Jorgensen IS, et al. Low 25-hydroxyvitamin D levels in adolescents: race, season, adiposity, physical activity, and fitness. *Pediatrics.* 2010;125:1104–1111. doi:10.1542/peds.2009-2055
51. Belsky DW, Huffman KM, Pieper CF, Shalev I, Kraus WE. Change in the rate of biological aging in response to caloric restriction: CALERIE biobank analysis. *J Gerontol A Biol Sci Med Sci.* 2017;73:4–10. doi:10.1093/gerona/glx096